Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110822 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 study of Multiple Myeloma, sponsored by Oncotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 13
- Study locations
NCT03110822: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Oncotherapeutics.
NCT03110822 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 134 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03110822, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Oncotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Primary Outcome
MTD will be determined by measuring incidence of the dose-limiting toxicities (DLTs) per dose level, of ruxolitinib in combination with steroids and lenalidomide for MM patients currently with progressive disease.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Methylprednisolone
- DRUG Ruxolitinib Oral Tablet [Jakafi]
Study Locations (13)
California
- Global Oncology, Inc. - Alhambra
- Comprehensive Blood and Cancer Center - Bakersfield
- California Cancer Associates for Research & Excellence (cCARE) - Encinitas
- Compassionate Care Research Group, Inc. - Fountain Valley
- Robert A. Moss, M.D., F.A.C.P., Inc. - Fountain Valley
- Pacific Cancer Care - Monterey
- Sansum Clinic- Ridley-Tree Cancer Center - Santa Barbara
- Wellness Oncology and Hematology - West Hills
- James R. Berenson M.D. Inc. - West Hollywood
Florida
- Cancer Specialists, LLC - Jacksonville
- Millennium Oncology Research Clinic - Pembroke Pines
Maryland
- Regional Cancer Care Associates (RCCA) MD, LLC - Bethesda
Washington
- Northwest Medical Specialists, PPLC - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT03110822 shows while recruiting
NCT03110822 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT03110822 lists 13 locations in 4 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT03110822 about?
NCT03110822 is a clinical study titled "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients". This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
What is the current status of trial NCT03110822?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2017-02-01. Estimated completion is 2027-02.
What conditions does trial NCT03110822 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03110822?
The interventions under investigation include: Lenalidomide (DRUG), Methylprednisolone (DRUG), Ruxolitinib Oral Tablet [Jakafi] (DRUG).
Who is sponsoring clinical trial NCT03110822?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03110822 being conducted?
This trial has 13 study locations across California, Florida, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03110822's enrollment target sits among peer trials
134 143rd of 438 higher than 296 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
- NCT05764720 · 134 participants · NA
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI